CD8+ TEMRAs in severe asthma associate with asthma symptom duration and escape proliferation arrest
JCI Insight · 22.04.2025 · 10 (8)
DOI: 10.1172/jci.insight.185061 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, online erschienen am 06.03.2025. Verfasst von Richard P Ramonell und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine. Hauptthemen laut MEDLINE: Asthma, CD8-Positive T-Lymphocytes, Memory T Cells. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIAID NIH HHS, NIH HHS.
Abstract (Originalsprache)
Aberrant immune response is a hallmark of asthma, with 5%–10% of patients suffering from severe disease exhibiting poor response to standard treatment. A better understanding of the immune responses contributing to disease heterogeneity is critical for improving asthma management. T cells are major players in the orchestration of asthma, in both mild and severe disease, but it is unclear whether specific T cell subsets influence asthma symptom duration. Here we show a significant association of airway CD8 + effector memory T cells re-expressing CD45RA (TEMRAs), but not CD8 + CD45RO + or tissue-resident memory T cells, with asthma duration in patients with severe asthma (SA) but not mild to moderate asthma (MMA). Higher frequencies of IFN-γ + CD8 + TEMRAs compared with IFN-γ + CD45RO + T cells were detected in SA airways, and the TEMRAs from patients with SA but not MMA proliferated ex vivo, although both expressed cellular senescence-associated biomarkers. Prompted by the transcriptomic profile of SA CD8 + TEMRAs and proliferative response to IL-15, airway IL15 expression was higher in patients with SA compared with MMA. Additionally, IL15 expression in asthmatic airways negatively correlated with lung function. Our findings add what we believe is a new dimension to understanding asthma heterogeneity, identifying IL-15 as a potential target for treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine.
- Asthma and Environmental Lung Health Institute at UPMC.
- Department of Immunology.
- Department of Cell Biology.
- Center for Biological Imaging.
- Department of Pediatrics.
Förderung
- NHLBI NIH HHS
- NIAID NIH HHS
- NIH HHS
Zitieren
APA
Ramonell, R. P., Oriss, T. B., McCreary-Partyka, J. C., Kale, S. L., Brandon, N. R., Ross, M. A., Gauthier, M. C., Yue, M., Nee, T. J., Das, S., Chen, W., Joglekar, A. V., Ray, P., St Croix, C. M., Rajasundaram, D., Wenzel, S. E., & Ray, A. (2025). CD8+ TEMRAs in severe asthma associate with asthma symptom duration and escape proliferation arrest. JCI Insight, 10(8). https://doi.org/10.1172/jci.insight.185061
Vancouver
Ramonell RP, Oriss TB, McCreary-Partyka JC, Kale SL, Brandon NR, Ross MA, et al. CD8+ TEMRAs in severe asthma associate with asthma symptom duration and escape proliferation arrest. JCI Insight. 2025;10(8). doi:10.1172/jci.insight.185061
BibTeX
@article{Ramonell2025,
author = {Ramonell, Richard P and Oriss, Timothy B and McCreary-Partyka, Jessica C and Kale, Sagar L and Brandon, Nicole R and Ross, Mark A and Gauthier, Marc C and Yue, Molin and Nee, Taylor J and Das, Sudipta and Chen, Wei and Joglekar, Alok V and Ray, Prabir and St Croix, Claudette M and Rajasundaram, Dhivyaa and Wenzel, Sally E and Ray, Anuradha},
title = {CD8+ TEMRAs in severe asthma associate with asthma symptom duration and escape proliferation arrest},
journal = {JCI Insight},
year = {2025},
volume = {10},
number = {8},
doi = {10.1172/jci.insight.185061}
}
EUVIMED